Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stellar Pharmaceuticals has launched its interstitial cystitis treatment Uracyst in the UK through G. Pohl-Boskamp GmbH, the company's exclusive Pan-European licensee for this product.
Subscribe to our email newsletter
Uracyst is formulated to treat interstitial cystitis (IC), an inflammatory disease of the urinary wall, the most common symptom of which is the need to urgently and frequently urinate. There is no known cure for IC, nor is there a dominant treatment in the market.
G. Pohl-Boskamp commenced sales of Uracyst in Germany, Austria, the Netherlands and Scandinavia in December 2003. Product sales in these countries have doubled, on a quarter-over-quarter basis, since their launch.
“The UK is one of Europe’s largest pharmaceutical markets, as well as one of the most sophisticated in terms of IC awareness,” commented Peter Riehl, president and CEO of Stellar. “We believe that the incidence of IC in the UK is similar in scope to the US, where at least 700,000 people are afflicted.”
Stellar also announced that G. Pohl-Boskamp GmbH received its first Health Insurance contract in Germany covering Uracyst. This is expected to favorably impact sales of this product in Germany, the home market for G. Pohl-Boskamp GmbH, since treatment costs associated with Uracyst are now fully reimbursable.